Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Lucintel | PRODUCT CODE: 1417560

Cover Image

PUBLISHER: Lucintel | PRODUCT CODE: 1417560

Peripheral Neuropathy Market Report: Trends, Forecast and Competitive Analysis to 2030

PUBLISHED:
PAGES: 150 - page report
DELIVERY TIME: 3 business days
SELECT AN OPTION
PDF (Single User License)
USD 4850
PDF (2 Users License)
USD 5800
PDF (5 Users License)
USD 6700
PDF (Corporate License)
USD 8850

Add to Cart

Peripheral Neuropathy Trends and Forecast

The future of the global peripheral neuropathy market looks promising with opportunities in the hospital and clinic and ambulatory center markets. The global peripheral neuropathy market is expected to grow with a CAGR of 7.0% from 2024 to 2030. The major drivers for this market are surge in geriatric and obese population and increasing occurence of diabetes.

A more than 150-page report is developed to help in your business decisions.

Peripheral Neuropathy by Segment

The study includes a forecast for the global peripheral neuropathy by type, treatment, end use, and region.

Peripheral Neuropathy Market by Type [Shipment Analysis by Value from 2018 to 2030]:

  • Diabetic Peripheral Neuropathy
  • Chemotherapy-Induced Peripheral Neuropathy
  • Idiopathic Peripheral Neuropathy
  • HIV/AIDS Associated Peripheral Neuropathy

Peripheral Neuropathy Market by Treatment [Shipment Analysis by Value from 2018 to 2030]:

  • Pharmacological Therapies
  • Non-Pharmacological Therapies
  • Others

Peripheral Neuropathy Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals and Clinics
  • Ambulatory Centers
  • Others

Peripheral Neuropathy Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Peripheral Neuropathy Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies peripheral neuropathy companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the peripheral neuropathy companies profiled in this report include-

  • Abbott
  • Bristol Myers Squibb
  • Novartis
  • Eli Lilly
  • Pfizer

Peripheral Neuropathy Market Insights

Lucintel forecasts that pharmacological therapy will remain the larger segment over the forecast period as it is more effective and easy to use.

Within this market, hospital and clinic will remain the larger segment due to availability of different treatment methods along with presence of expertise in these facilities.

North America will remain the largest region over the forecast period due to high prevalence of diabetes patients and presence of healthcare infrastructure in the region.

Features of the Global Peripheral Neuropathy Market

Market Size Estimates: Peripheral neuropathy market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Peripheral neuropathy market size by type, treatment, end use, and region in terms of value ($B).

Regional Analysis: Peripheral neuropathy market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, treatment, end uses, and regions for the peripheral neuropathy market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the peripheral neuropathy market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the growth forecast for peripheral neuropathy market?

Answer: The global peripheral neuropathy market is expected to grow with a CAGR of 7.0% from 2024 to 2030.

Q2. What are the major drivers influencing the growth of the peripheral neuropathy market?

Answer: The major drivers for this market are surge in geriatric and obese population and increasing occurence of diabetes.

Q3. What are the major segments for peripheral neuropathy market?

Answer: The future of the peripheral neuropathy market looks promising with opportunities in the hospital and clinic and ambulatory center markets.

Q4. Who are the key peripheral neuropathy market companies?

Answer: Some of the key peripheral neuropathy companies are as follows.

  • Abbott
  • Bristol Myers Squibb
  • Novartis
  • Eli Lilly
  • Pfizer

Q5. Which peripheral neuropathy market segment will be the largest in future?

Answer: Lucintel forecasts that pharmacological therapy will remain the larger segment over the forecast period as it is more effective and easy to use.

Q6. In peripheral neuropathy market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to high prevalence of diabetes patients and presence of healthcare infrastructure in the region.

Q7. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the peripheral neuropathy market by type (diabetic peripheral neuropathy, chemotherapy-induced peripheral neuropathy, idiopathic peripheral neuropathy, and HIV/AIDS associated peripheral neuropathy), treatment (pharmacological therapies, non-pharmacological therapies, and others), end use (hospitals and clinics, ambulatory centers, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Peripheral Neuropathy Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Peripheral Neuropathy Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Peripheral Neuropathy Market by Type
    • 3.3.1: Diabetic Peripheral Neuropathy
    • 3.3.2: Chemotherapy-induced Peripheral Neuropathy
    • 3.3.3: Idiopathic Peripheral Neuropathy
    • 3.3.4: HIV/AIDS Associated Peripheral Neuropathy
  • 3.4: Global Peripheral Neuropathy Market by Treatment
    • 3.4.1: Pharmacological Therapies
    • 3.4.2: Non-Pharmacological Therapies
    • 3.4.3: Others
  • 3.5: Global Peripheral Neuropathy Market by End Use
    • 3.5.1: Hospitals and Clinics
    • 3.5.2: Ambulatory Centers
    • 3.5.3: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Peripheral Neuropathy Market by Region
  • 4.2: North American Peripheral Neuropathy Market
    • 4.2.1: North American Peripheral Neuropathy Market by Treatment: Pharmacological Therapies, Non-Pharmacological Therapies, and Others
    • 4.2.2: North American Peripheral Neuropathy Market by End Use: Hospitals and Clinics, Ambulatory Centers, and Others
  • 4.3: European Peripheral Neuropathy Market
    • 4.3.1: European Peripheral Neuropathy Market by Treatment: Pharmacological Therapies, Non-Pharmacological Therapies, and Others
    • 4.3.2: European Peripheral Neuropathy Market by End Use: Hospitals and Clinics, Ambulatory Centers, and Others
  • 4.4: APAC Peripheral Neuropathy Market
    • 4.4.1: APAC Peripheral Neuropathy Market by Treatment: Pharmacological Therapies, Non-Pharmacological Therapies, and Others
    • 4.4.2: APAC Peripheral Neuropathy Market by End Use: Hospitals and Clinics, Ambulatory Centers, and Others
  • 4.5: ROW Peripheral Neuropathy Market
    • 4.5.1: ROW Peripheral Neuropathy Market by Treatment: Pharmacological Therapies, Non-Pharmacological Therapies, and Others
    • 4.5.2: ROW Peripheral Neuropathy Market by End Use: Hospitals and Clinics, Ambulatory Centers, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Peripheral Neuropathy Market by Type
    • 6.1.2: Growth Opportunities for the Global Peripheral Neuropathy Market by Treatment
    • 6.1.3: Growth Opportunities for the Global Peripheral Neuropathy Market by End Use
    • 6.1.4: Growth Opportunities for the Global Peripheral Neuropathy Market by Region
  • 6.2: Emerging Trends in the Global Peripheral Neuropathy Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Peripheral Neuropathy Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Peripheral Neuropathy Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Abbott
  • 7.2: Bristol Myers Squibb
  • 7.3: Novartis
  • 7.4: Eli Lilly
  • 7.5: Pfizer
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!